List view / Grid view
In this article, Drug Target Review’s Ria Kakkad explores the importance of diverse and inclusive samples in genomic studies with Assistant Professor Lindsay Fernández-Rhodes, Pennsylvania State University.
Scientists have created what they believe is the first rat model of Down’s syndrome. The animal model shares features with human Down’s syndrome, which will allow for efficient testing of new therapies.
Researchers have found that genes in small organisms, known to extend lifespan, could also impact ageing in humans.
Dr Greg Neely, University of Sydney, explains how he and his team used pooled whole genome CRISPR activation screening to identify LRRC15 as a SARS-CoV-2 spike-interacting protein.
The new study identified PDZ-binding kinase (PBK) as a promising target for pulmonary hypertension and assessed two PBK inhibitors.
The new study looked at the network of gene-gene interactions associated with cancer onset and progression to identify therapeutic targets.
Scientists identified three prototypical RNA-expression states and revealed differences in their susceptibility to a variety of cancer drugs.
Researchers developed a patient-specific zebrafish model for arrhythmogenic cardiomyopathy (ACM) and tested istaroxime as a potential therapeutic.
The exciting new study demonstrates how the technology could be used to improve animal welfare in scientific research and agriculture.
Scientists used a new screen to identify FAM72A as a cause of mutagenesis that affects antibody development in COVID-19 and cancer.
The study is the first in-depth look at links between COVID-19 severity and gene expression in immune cells and may guide future therapies.
Scientists used a CRISPR-based screen to find that inhibiting MTHFD2 reduces disease severity in inflammatory disease models.
The antihypertensive drug candesartan cilexetil reduced matrisomal protein accumulation in mice with cerebral small vessel disease.
Scientists reveal that higher levels of inflammatory chemicals involved in fat metabolism occur in people with amyotrophic lateral sclerosis.
An experimental drug for liver cancer and Dasatinib, approved for chronic myeloid leukaemia could be repurposed to treat Alzheimer's disease.
